Pipeline Moves: Alnylam's Amvuttra approval prospects up after Phase III win

By Yahoo! Finance | Jul 8, 2024 at 04:59 AM EST

Alnylam's Amvuttra shows promise in familial amyloid cardiomyopathy, Shionogi's S-309309 progresses in obesity, and Junshi Biosciences faces setbacks in ovarian cancer trials. These developments impact drug approval and advancement probabilities.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.